RYTM Rhythm Pharmaceuticals Inc.

30.37
+0.1  (+0%)
Previous Close 30.27
Open 30.62
Price To Book 4.25
Market Cap 1045512457
Shares 34,425,830
Volume 67,504
Short Ratio
Av. Daily Volume 81,264

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data due "in the near future" - noted March 8, 2019.
Setmelanotide
POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders
Phase 3 data due 2020.
Setmelanotide
Alstrom Syndrome and Bardet-Biedl Syndrome
Phase 3 initial data due 3Q 2019.
Setmelanotide
Leptin Receptor Deficiency Obesity
Phase 3 initial data due 3Q 2019.
Setmelanotide
POMC deficiency obesity